{"id":71803,"date":"2024-11-20T17:01:04","date_gmt":"2024-11-20T16:01:04","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=71803"},"modified":"2024-11-20T17:01:11","modified_gmt":"2024-11-20T16:01:11","slug":"stopping-severe-malaria-by-harnessing-natural-human-antibodies","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/","title":{"rendered":"Stopping severe malaria by harnessing natural human antibodies"},"content":{"rendered":"\n<article class=\"vf-card vf-card--brand vf-card--bordered vf-u-margin__bottom--800\" default>\n  <div class=\"vf-card__content | vf-stack vf-stack--400\">\n      <h3 class=\"vf-card__heading\">\n      Summary    <\/h3>\n                <p class=\"vf-card__text\"><ul>\r\n \t<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Scientists have identified human antibodies capable of targeting the proteins responsible for severe malaria, potentially paving the way for new vaccines or treatments.\r\n<\/span><\/li>\r\n \t<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Using organ-on-a-chip technology, researchers successfully demonstrated that these antibodies prevent infected red blood cells from adhering to vessel walls, a key driver of severe malaria symptoms.\r\n<\/span><\/li>\r\n \t<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The antibodies neutralise a conserved region of the malarial protein PfEMP1, overcoming its notorious variability and shedding light on acquired immunity mechanisms.\r\n<\/span><\/li>\r\n \t<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">This interdisciplinary study, published in <em>Nature<\/em>, highlights the power of international teamwork in addressing major health challenges like malaria.\r\n<\/span><\/li>\r\n<\/ul><\/p>\n      <\/div>\n<\/article>\n\n\n\n\n<p>Malaria, particularly in its severe forms, remains a global health and economic burden. It causes the deaths of more than 600,000 people every year \u2013 most of them African children under five. In a new study, published in the journal <a href=\"http:\/\/www.nature.com\/articles\/s41586-024-08220-3\"><em>Nature<\/em><\/a><em>,<\/em> researchers from EMBL Barcelona, the University of Texas, the University of Copenhagen, and The Scripps Research Institute have discovered human antibodies that can recognise and target some of the proteins that cause severe malaria. This breakthrough could pave the way for future vaccines or anti-malaria treatments.<\/p>\n\n\n\n<p>Severe malaria is caused by the parasite <em>Plasmodium falciparum, <\/em>which infects and modifies red blood cells. These modifications can make the red blood cells stick to the walls of tiny blood vessels in the brain. This results in impaired blood flow and blockage of small blood vessels, which causes brain swelling and can develop into cerebral malaria.&nbsp;<\/p>\n\n\n\n<p>The blockage of blood flow is primarily driven by a family of about 60 virulent proteins, called PfEMP1, present on the surface of infected red blood cells. Some types of PfEMP1 proteins can attach to another human protein called EPCR on the surface of cells lining blood vessels. This interaction damages blood vessels and is closely linked to the development of life-threatening complications.&nbsp;<\/p>\n\n\n\n<p>The researchers knew that when children in Africa grow older, they progressively develop immunity, and teenagers and adults rarely suffer from lethal disease complications. This protection was thought to be mediated by antibodies that target PfEMP1.&nbsp;<\/p>\n\n\n\n<p>PfEMP1 is a highly variable protein and has long been considered a technically difficult vaccine target. A long-standing question therefore has been whether the immune system can generate antibodies\u2014proteins that recognise and neutralise specific pathogens\u2014that can target the wide variety of PfEMP1 types in circulation.&nbsp;<\/p>\n\n\n\n<p>\u201cWe were hesitant whether we could identify a single antibody that could recognise them all,\u201d said Maria Bernabeu, co-senior author of the paper and Group Leader at EMBL Barcelona, \u201cAnd it turned out that our improved immunological screening methods developed at the University of Texas quickly identified two examples of human antibodies broadly effective against different versions of the PfEMP1 protein. They both targeted a part of the protein known as CIDR\u03b11 which interacts with the EPCR receptor.\u201d<\/p>\n\n\n\n<p>The team then needed to test if those antibodies could also successfully block EPCR binding in living blood vessels. In most diseases, this could have been tested in animal models. However, for malaria, this is not possible because the virulent proteins of the parasites that infect mice are very different from their human counterparts.&nbsp;<\/p>\n\n\n\n<p>The researchers came up with an innovative approach to overcome this challenge. They developed a way to grow a network of human blood vessels in the laboratory and to pass human blood infected with live parasites through the vessels, thereby reconstructing the disease in a dish. These experiments demonstrated that the antibodies were able to prevent the infected cells from accumulating, suggesting they might help stop the blockage that leads to severe malaria symptoms.<\/p>\n\n\n\n<p>\u201cWe used our organ-on-a-chip technology to recreate brain microvessels in 3D, which we then infected with malaria parasites,\u201d said Viola Introini, Marie-Sk\u0142odowska Curie postdoctoral fellow in Maria Bernabeu\u2019s Group at EMBL Barcelona and co-first author of the work. \u201cWe introduced the two antibodies into the vasculature and were impressed at how well they prevented infected blood cells from sticking to the vessels. It was striking to see inhibition readily apparent by eye.\u201d&nbsp;<\/p>\n\n\n\n<figure class=\"vf-figure wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"615\" class=\"vf-figure__image\" src=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix2-1024x615.jpg\" alt=\"\" class=\"wp-image-71807\" srcset=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix2-1024x615.jpg 1024w, https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix2-300x180.jpg 300w, https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix2-768x461.jpg 768w, https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix2.jpg 1333w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"vf-figure__caption\">Microfluidic device where the researchers recreated a 3D model of the blood brain barrier. Credit: Carla Manzanas\/EMBL<\/figcaption><\/figure>\n\n\n\n<p>Structural and immunology analysis by collaborators at the University of Copenhagen and The Scripps Research Institute revealed that these antibodies prevent parasite binding by a similar mechanism \u2013 recognising three highly conserved amino acids on CIDR\u03b11. These broadly reactive antibodies likely represent a common mechanism of acquired immunity to severe malaria and offer novel insights for the design of a PfEMP1-based vaccine or treatment targeting severe malaria.<\/p>\n\n\n\n<p>\u201cThis study opens the door to targeting new ways of protecting people from severe malaria, like a vaccine or other treatments,\u201d said Bernabeu. \u201cThis is thanks to the international and interdisciplinary collaboration that is key to understanding diseases like malaria. Our collaborators are from across the globe, studying malaria from different angles. We have to continue working together to tackle big challenges like this one.\u201d<\/p>\n\n\n\n<p>She added: \u201cAt EMBL Barcelona, we believe that tissue engineering and growing organs-on-a-chip allow us to study diseases with much more complexity and detail, as well as provide useful platforms for screening vaccine candidates.\u201d<\/p>\n\n\n\n<hr class=\"vf-divider\"\/>\n\n\n\n<h1 class=\"wp-block-heading\" id=\"spanish\">Detener la malaria severa a trav\u00e9s de anticuerpos humanos naturales<\/h1>\n\n\n\n<h2 class=\"wp-block-heading\">Cient\u00edficos identifican anticuerpos humanos que podr\u00edan prevenir infecciones de malaria potencialmente mortales<\/h2>\n\n\n\n<article class=\"vf-card vf-card--brand vf-card--bordered vf-u-margin__bottom--800\" default>\n  <div class=\"vf-card__content | vf-stack vf-stack--400\">\n      <h3 class=\"vf-card__heading\">\n      Resumen    <\/h3>\n                <p class=\"vf-card__text\"><ul>\r\n \t<li aria-level=\"1\">Investigadores descubren anticuerpos humanos capaces de atacar a las prote\u00ednas responsables de la malaria severa, lo que abre la puerta al desarrollo de nuevas vacunas o tratamientos.<\/li>\r\n \t<li aria-level=\"1\">Utilizando tecnolog\u00eda de \u00f3rganos-en-chips, los investigadores demostraron que estos anticuerpos impiden que los gl\u00f3bulos rojos infectados se adhieran a las paredes de los vasos sangu\u00edneos, un mecanismo clave detr\u00e1s de los s\u00edntomas de malaria severa.<\/li>\r\n \t<li aria-level=\"1\">Los anticuerpos neutralizan una regi\u00f3n conservada de la prote\u00edna de malaria PfEMP1, superando su conocida variabilidad y aportando informaci\u00f3n sobre los mecanismos de inmunidad generada para evitar la enfermedad severa.<\/li>\r\n \t<li aria-level=\"1\">Este estudio interdisciplinario, publicado en la revista <i>Nature<\/i>, destaca el poder de la colaboraci\u00f3n internacional para abordar retos importantes en la salud global, como la malaria.<\/li>\r\n<\/ul><\/p>\n      <\/div>\n<\/article>\n\n\n\n\n<p>La malaria, especialmente en sus formas severas, sigue siendo un reto global&nbsp; tanto a nivel sanitario como econ\u00f3mico. Provoca m\u00e1s de 600,000 muertes al a\u00f1o, principalmente entre ni\u00f1os africanos menores de cinco a\u00f1os. En este estudio publicado en la revista <em><a href=\"http:\/\/www.nature.com\/articles\/s41586-024-08220-3\">Nature<\/a><\/em>, investigadores del EMBL Barcelona, la Universidad de Texas, la Universidad de Copenhague y el Instituto de Investigaci\u00f3n Scripps han identificado anticuerpos humanos capaces de reconocer y atacar algunas de las prote\u00ednas que provocan malaria grave. Este descubrimiento representa un avance prometedor hacia el desarrollo de futuras vacunas o tratamientos contra la malaria.<\/p>\n\n\n\n<p>La malaria grave est\u00e1 causada por el par\u00e1sito <em>Plasmodium falciparum<\/em>, que infecta y modifica los gl\u00f3bulos rojos. Estas modificaciones pueden hacer que los gl\u00f3bulos rojos se adhieran a las paredes de peque\u00f1os vasos sangu\u00edneos en el cerebro, lo que provoca un flujo sangu\u00edneo deficiente y bloqueos en el sistema vascular. Esto lleva a una inflamaci\u00f3n cerebral que puede desencadenar malaria cerebral.<\/p>\n\n\n\n<p>El bloqueo del flujo sangu\u00edneo se debe principalmente a una familia de alrededor de 60 prote\u00ednas virulentas llamadas PfEMP1, presentes en la superficie de los gl\u00f3bulos rojos infectados. Algunos tipos de prote\u00ednas PfEMP1 pueden unirse a otra prote\u00edna humana llamada EPCR, que se encuentra en las c\u00e9lulas que recubren los vasos sangu\u00edneos. Esta interacci\u00f3n da\u00f1a los vasos y est\u00e1 estrechamente relacionada con el desarrollo de complicaciones potencialmente mortales.<\/p>\n\n\n\n<p>Los investigadores sab\u00edan que, a medida que los ni\u00f1os africanos crecen, desarrollan progresivamente inmunidad, y los adolescentes y adultos rara vez padecen complicaciones letales de la enfermedad. Se cre\u00eda que esta protecci\u00f3n estaba mediada por anticuerpos dirigidos contra PfEMP1.<\/p>\n\n\n\n<p>PfEMP1 es una prote\u00edna altamente variable y durante mucho tiempo se consider\u00f3 t\u00e9cnicamente dif\u00edcil desarrollar una vacuna basada en ella. Una pregunta central era si el sistema inmunol\u00f3gico podr\u00eda generar anticuerpos \u2014prote\u00ednas que reconocen y neutralizan pat\u00f3genos espec\u00edficos\u2014 capaces de atacar la amplia variedad de tipos de PfEMP1 presentes en circulaci\u00f3n.<\/p>\n\n\n\n<p>\u201cDud\u00e1bamos si podr\u00edamos identificar un \u00fanico anticuerpo que pudiera reconocer todas las variantes\u201d, se\u00f1ala Maria Bernabeu, coautora s\u00e9nior del estudio e investigadora principal en EMBL Barcelona. \u201cResult\u00f3 que gracias a m\u00e9todos de cribado inmunol\u00f3gico mejorados, desarrollados en la Universidad de Texas, r\u00e1pidamente identificamos dos ejemplos de anticuerpos humanos que son ampliamente efectivos contra diferentes versiones de la prote\u00edna PfEMP1. Ambos anticuerpos se dirigieron a una parte de la prote\u00edna conocida como CIDR\u03b11, que interact\u00faa con el receptor EPCR\u201d.<\/p>\n\n\n\n<p>El equipo necesitaba comprobar si estos anticuerpos podr\u00edan bloquear con \u00e9xito la uni\u00f3n a EPCR en vasos sangu\u00edneos vivos. En la mayor\u00eda de las enfermedades, esto podr\u00eda haberse probado en modelos animales. Sin embargo, en el caso de la malaria, esto no es posible, ya que las prote\u00ednas virulentas de los par\u00e1sitos que infectan a los ratones son muy diferentes de las de los humanos.<\/p>\n\n\n\n<p>Para superar este desaf\u00edo, los investigadores desarrollaron un enfoque innovador. Cultivaron una red de vasos sangu\u00edneos humanos en el laboratorio y pasaron sangre humana infectada con par\u00e1sitos vivos a trav\u00e9s de ellos, reconstruyendo la enfermedad en un sistema experimental. Estos experimentos demostraron que los anticuerpos eran capaces de evitar que las c\u00e9lulas infectadas se acumularan, lo que sugiere que podr\u00edan ayudar a prevenir los bloqueos responsables de los s\u00edntomas graves de la malaria.<\/p>\n\n\n\n<p>\u201cUsamos nuestra tecnolog\u00eda de \u00f3rgano-en-chip para recrear microvasos cerebrales en 3D, que luego infectamos con par\u00e1sitos de malaria\u201d, explica Viola Introini, postdoc Marie-Sk\u0142odowska Curie en el grupo de Maria Bernabeu en EMBL Barcelona y co-autora principal del estudio. \u201cIntrodujimos los dos anticuerpos en el sistema vascular y nos impresion\u00f3 lo bien que evitaron que los gl\u00f3bulos rojos infectados se adhirieran a los vasos. Era sorprendente ver la inhibici\u00f3n de manera tan evidente a simple vista\u201d.<\/p>\n\n\n\n<p>An\u00e1lisis estructurales e inmunol\u00f3gicos realizados por colaboradores de la Universidad de Copenhague y el Instituto de Investigaci\u00f3n Scripps revelaron que estos anticuerpos previenen la uni\u00f3n del par\u00e1sito mediante un mecanismo similar: reconocen tres amino\u00e1cidos altamente conservados en CIDR\u03b11. Estos anticuerpos ampliamente reactivos probablemente representan un mecanismo com\u00fan de inmunidad adquirida frente a la malaria grave y ofrecen nuevas perspectivas para el dise\u00f1o de una vacuna o tratamiento basado en PfEMP1 contra la malaria severa.<\/p>\n\n\n\n<p>\u201cEste estudio abre la puerta a nuevas formas de proteger a las personas de la malaria grave, como una vacuna o tratamientos adicionales\u201d, afirma Bernabeu. \u201cEsto ha sido posible gracias a la colaboraci\u00f3n internacional e interdisciplinaria, que es clave para entender enfermedades como la malaria. Nuestros colaboradores provienen de todo el mundo y abordan la malaria desde diferentes perspectivas. Debemos seguir trabajando juntos para enfrentar desaf\u00edos importantes como este\u201d.<\/p>\n\n\n\n<p>A\u00f1adi\u00f3: \u201cEn EMBL Barcelona, creemos que la ingenier\u00eda de tejidos y el cultivo de \u00f3rganos-en-chip nos permiten estudiar enfermedades con mucha m\u00e1s complejidad y detalle, adem\u00e1s de proporcionar plataformas \u00fatiles para evaluar candidatos a vacunas\u201d.<\/p>\n\n\n\n<hr class=\"vf-divider\"\/>\n\n\n\n<h1 class=\"wp-block-heading\" id=\"italian\"><strong>Sfruttare anticorpi isolati dai pazienti per prevenire la malaria cerebrale<\/strong><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\">Un gruppo di scienziati ha identificato degli anticorpi che potrebbero impedire al parassita della malaria di causare infezioni letali<\/h2>\n\n\n\n<article class=\"vf-card vf-card--brand vf-card--bordered vf-u-margin__bottom--800\" default>\n  <div class=\"vf-card__content | vf-stack vf-stack--400\">\n      <h3 class=\"vf-card__heading\">\n      Sintesi    <\/h3>\n                <p class=\"vf-card__text\"><ul>\r\n \t<li aria-level=\"1\">Un team di ricercatori ha identificato due anticorpi prodotti naturalmente da individui infetti in grado di bloccare le proteine prodotte dal parassita, aprendo potenzialmente la strada a nuovi vaccini o trattamenti.<\/li>\r\n \t<li aria-level=\"1\">Utilizzando la tecnologia \u201corgan-on-a-chip\u201d, i ricercatori hanno dimostrato con successo che questi anticorpi impediscono ai globuli rossi infetti di aderire alle pareti dei vasi sanguigni, un meccanismo chiave alla base dei sintomi della malaria.<\/li>\r\n \t<li aria-level=\"1\">Gli anticorpi neutralizzano una regione della proteina PfEMP1, prodotta dal parassita, superando le difficolt\u00e0 dovute alla sua nota variabilit\u00e0 e facendo luce sui meccanismi dell&#8217;immunit\u00e0 acquisita.<\/li>\r\n \t<li aria-level=\"1\">Questo studio interdisciplinare, pubblicato su Nature, evidenzia il valore della collaborazione internazionale per affrontare grandi sfide sanitarie come la malaria.<\/li>\r\n<\/ul><\/p>\n      <\/div>\n<\/article>\n\n\n\n\n<p>La malaria, soprattutto nelle sue forme gravi, rimane un onere sanitario ed economico globale. Ogni anno, causa la morte di oltre 600.000 persone, la maggior parte delle quali sono bambini sotto i cinque anni che vivono in regioni dell\u2019Africa subsahariana. In un nuovo studio pubblicato sulla rivista Nature, i ricercatori dell&#8217; EMBL di Barcellona, dell&#8217;Universit\u00e0 del Texas, dell&#8217;Universit\u00e0 di Copenaghen e dello Scripps Research Institute hanno isolato&nbsp; anticorpi da persone precedentemente affette da malaria, in grado di riconoscere e inibire&nbsp; alcune delle proteine che causano i gravi sintomi associati alla malaria. Questa scoperta potrebbe aprire la strada a futuri vaccini o trattamenti antimalarici.<\/p>\n\n\n\n<p>La forma di parassita pi\u00f9 pericolosa \u00e8 il <em>Plasmodium falciparum<\/em>, che infetta e modifica i globuli rossi. Queste modifiche possono causare l\u2019adesione dei globuli rossi alle pareti dei capillari&nbsp; del cervello. Questo provoca un&#8217;alterazione del flusso sanguigno e l&#8217;ostruzione dei vasi sanguigni, causando un rigonfiamento del cervello che pu\u00f2 evolvere in malaria cerebrale.&nbsp;<\/p>\n\n\n\n<p>Il blocco del flusso sanguigno \u00e8 determinato principalmente da una famiglia di circa 60 proteine virulente, chiamate PfEMP1, presenti sulla superficie dei globuli rossi infetti. Alcuni tipi di proteine PfEMP1 possono aderire al recettore EPCR sulla superficie delle cellule endoteliali che rivestono i vasi sanguigni. Questa interazione danneggia i vasi sanguigni ed \u00e8 strettamente legata allo sviluppo di complicazioni potenzialmente letali.<\/p>\n\n\n\n<p>\u00c8 noto da studi precedenti che i bambini che sopravvivono alla malaria, una volta cresciuti, sviluppano progressivamente l&#8217;immunit\u00e0 e che gli adolescenti e gli adulti raramente soffrono di complicazioni letali della malattia. Si \u00e8 ipotizzato che questa protezione derivasse da anticorpi che bloccano la PfEMP1.&nbsp;<\/p>\n\n\n\n<p>PfEMP1 \u00e8 una proteina altamente variabile ed \u00e8 stata a lungo considerata un bersaglio tecnicamente difficile per lo sviluppo di un vaccino. Da tempo ci si chiede se il sistema immunitario sia in grado di generare anticorpi &#8211; proteine che riconoscono e neutralizzano specifici agenti patogeni &#8211; in grado di colpire l&#8217;ampia variet\u00e0 di tipi di PfEMP1 in circolazione.<\/p>\n\n\n\n<p>\u201cNon eravamo sicuri di riuscire a identificare un singolo anticorpo in grado di riconoscerli tutti\u201d, ha dichiarato Maria Bernabeu, coautrice del lavoro e group leader presso l\u2019 EMBL di Barcellona, \u201cma i metodi di screening immunologico che abbiamo perfezionato, sviluppati presso l&#8217;Universit\u00e0 del Texas, hanno rapidamente identificato due esempi di anticorpi umani altamente efficaci contro diverse versioni della proteina PfEMP1. Entrambi hanno come bersaglio una regione della proteina nota come CIDR\u03b11 che interagisce con il recettore EPCR\u201d.<\/p>\n\n\n\n<p>Il passo successivo \u00e8 stato verificare&nbsp; se questi anticorpi potessero bloccare con successo il legame tra PfEMP1 ed EPCR anche nei vasi sanguigni <em>in vivo<\/em>. Per la maggior parte delle malattie, questo potrebbe essere testato in modelli animali. Tuttavia, nel caso della malaria, ci\u00f2 non \u00e8 possibile perch\u00e9 le proteine virulente dei parassiti che infettano i topi sono molto diverse da quelle che infettano gli umani.<\/p>\n\n\n\n<p>I ricercatori hanno proposto un approccio innovativo per superare questa sfida. Hanno sviluppato un modo per creare una rete di vasi sanguigni umani in laboratorio e far passare il sangue umano infettato da parassiti vivi attraverso i vasi, riproducendo cos\u00ec lo sviluppo della malattia in laboratorio. Gli esperimenti hanno dimostrato che gli anticorpi sono in grado di impedire l&#8217;accumulo di cellule infette, limitando i problemi circolatori che che portano a gravi sintomi.<\/p>\n\n\n\n<p>\u201cAbbiamo utilizzato la nostra tecnologia organ-on-a-chip per ricreare vasi sanguigni cerebrali di centinaia di micrometri , che abbiamo poi infettato con i parassiti della malaria\u201d, ha dichiarato Viola Introini, post-dottoranda con una borsa europea Marie-Sk\u0142odowska Curie nel gruppo di Maria Bernabeu presso l&#8217; EMBL di Barcellona e prima coautrice del lavoro. \u201cAbbiamo introdotto i due anticorpi nei vasi e siamo rimasti colpiti dall&#8217;efficacia con cui hanno impedito alle cellule sanguigne infette di aderire ai vasi. \u00c8 stato sorprendente osservare facilmente l&#8217;inibizione anche ad occhio nudo\u201d.&nbsp;<\/p>\n\n\n\n<p>Le analisi strutturali e immunologiche condotte dai collaboratori dell&#8217;Universit\u00e0 di Copenhagen e del The Scripps Research Institute hanno rivelato che questi anticorpi impediscono il legame con il parassita con un meccanismo simile, riconoscendo tre amminoacidi conservati nella regione CIDR\u03b11. Questi anticorpi altamente reattivi sembrano indicare un meccanismo comune di immunit\u00e0 acquisita contro severe forme di malaria&nbsp; e offrono nuovi spunti per la progettazione di un vaccino o di un trattamento contro PfEMP1.<\/p>\n\n\n\n<p>\u201cQuesto studio apre le porte a nuovi modi per proteggere le persone dalla malaria cerebrale, come un vaccino o altri trattamenti\u201d, ha dichiarato Bernabeu. \u201cQuesto grazie alla collaborazione internazionale e interdisciplinare che \u00e8 fondamentale per comprendere malattie complesse come la malaria. I nostri collaboratori provengono da tutto il mondo e studiano la malaria da diverse angolazioni. Dobbiamo continuare a lavorare insieme per affrontare grandi sfide come questa\u201d.<\/p>\n\n\n\n<p>Bernabeu ha infine aggiunto \u201cAll&#8217; EMBL di Barcellona crediamo che l&#8217;ingegneria dei tessuti e la coltivazione di organi su chip ci permettano di studiare le malattie con maggiore complessit\u00e0 e dettaglio, oltre a fornire piattaforme utili per lo screening di candidati per lo sviluppo di vaccini\u201d.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The findings of the study provide insights into vaccines or treatments to protect people from severe malaria.<\/p>\n","protected":false},"author":94,"featured_media":71805,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[17591],"tags":[497,984,5630,330,431],"embl_taxonomy":[19173,9762,19021,5154],"class_list":["post-71803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science-technology","tag-barcelona","tag-bernabeu","tag-cerebral-malaria","tag-malaria","tag-tissue-biology","embl_taxonomy-bernabeu-group","embl_taxonomy-embl-barcelona","embl_taxonomy-maria-bernabeu-aznar","embl_taxonomy-tissue-biology-and-disease-modelling"],"acf":{"featured":true,"show_featured_image":false,"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"article_intro":"<p>Scientists have identified human antibodies that could prevent the malaria parasite from causing life-threatening infections<\/p>\n","related_links":[{"link_description":"Bernabeu Group","link_url":"https:\/\/www.embl.org\/groups\/bernabeu\/"},{"link_description":"Organs-on-chip: new horizons for disease research","link_url":"https:\/\/www.embl.org\/news\/embletc\/issue-100\/organs-on-chip-new-horizons-for-disease-research\/"}],"source_article":[{"publication_title":"Broadly inhibitory antibodies to severe malaria virulence proteins","publication_link":{"title":"","url":"http:\/\/www.nature.com\/articles\/s41586-024-08220-3","target":""},"publication_authors":"Reyes R., et al.","publication_source":"Nature","publication_date":"11\/2024","publication_doi":"10.1038\/s41586-024-08220-3"}],"in_this_article":false,"press_contact":"EMBL Generic","article_translations":[{"translation_language":"Espa\u00f1ol","translation_anchor":"#spanish"},{"translation_language":"Italiano","translation_anchor":"#italian"}],"languages":""},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"302cfdf7-365b-462a-be65-82c7b783ebf7\";i:1;s:36:\"18a7a17b-e276-4afd-b0ca-8ddac1883d45\";i:2;s:36:\"71aeb1fd-6b3c-4f66-bae8-a09e9fbedf58\";}","parents":[],"name":["Bernabeu Group"],"slug":"bernabeu-group","description":"What &gt; Tissue biology and disease modelling &gt; Bernabeu Group"},{"uuid":"a:3:{i:0;s:36:\"b14d3f13-5670-44fb-8970-e54dfd9c921a\";i:1;s:36:\"89e00fee-87f4-482e-a801-4c3548bb6a58\";i:2;s:36:\"762176bb-d12e-4c94-8964-6dbb76e15c42\";}","parents":[],"name":["EMBL Barcelona"],"slug":"embl-barcelona","description":"Where &gt; All EMBL sites &gt; EMBL Barcelona"},{"uuid":"a:2:{i:0;s:36:\"4428d1fd-441a-4d6d-a1c5-5dcf5665f213\";i:1;s:36:\"3df4726b-ca23-445c-913f-d70d0e7a2642\";}","parents":[],"name":["Maria Bernabeu Aznar"],"slug":"maria-bernabeu-aznar","description":"Who &gt; Maria Bernabeu Aznar"},{"uuid":"a:3:{i:0;s:36:\"302cfdf7-365b-462a-be65-82c7b783ebf7\";i:1;s:36:\"7ca3ce91-dc32-47ea-8d4b-7a53c3a3a9fd\";i:2;s:36:\"18a7a17b-e276-4afd-b0ca-8ddac1883d45\";}","parents":[],"name":["Tissue biology and disease modelling"],"slug":"tissue-biology-and-disease-modelling","description":"What &gt; Research Units &gt; Tissue biology and disease modelling"}],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Stopping severe malaria by harnessing natural human antibodies | EMBL<\/title>\n<meta name=\"description\" content=\"The findings of the study provide insights into vaccines or treatments to protect people from severe malaria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stopping severe malaria by harnessing natural human antibodies | EMBL\" \/>\n<meta property=\"og:description\" content=\"The findings of the study provide insights into vaccines or treatments to protect people from severe malaria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-20T16:01:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-20T16:01:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Carla Manzanas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Carla Manzanas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/\"},\"author\":{\"name\":\"Carla Manzanas\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/40c2c3096ae3f56b1304b22fb8c0efb1\"},\"headline\":\"Stopping severe malaria by harnessing natural human antibodies\",\"datePublished\":\"2024-11-20T16:01:04+00:00\",\"dateModified\":\"2024-11-20T16:01:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/\"},\"wordCount\":2493,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg\",\"keywords\":[\"barcelona\",\"bernabeu\",\"cerebral malaria\",\"malaria\",\"tissue biology\"],\"articleSection\":[\"Science &amp; Technology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/\",\"url\":\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/\",\"name\":\"Stopping severe malaria by harnessing natural human antibodies | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg\",\"datePublished\":\"2024-11-20T16:01:04+00:00\",\"dateModified\":\"2024-11-20T16:01:11+00:00\",\"description\":\"The findings of the study provide insights into vaccines or treatments to protect people from severe malaria.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg\",\"width\":1000,\"height\":600,\"caption\":\"Viola Introini and Maria Bernabeu, authors of a new study on antibodies against virulent proteins responsible for severe malaria, at the PRBB. Credit: Carla Manzanas\/EMBL\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/40c2c3096ae3f56b1304b22fb8c0efb1\",\"name\":\"Carla Manzanas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/14ed25b349f20c950811a10cef35721ed66d9f8d136445e2d53bb0dd811984f1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/14ed25b349f20c950811a10cef35721ed66d9f8d136445e2d53bb0dd811984f1?s=96&d=mm&r=g\",\"caption\":\"Carla Manzanas\"},\"url\":\"https:\/\/www.embl.org\/news\/author\/carlamanzanas-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2--2\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stopping severe malaria by harnessing natural human antibodies | EMBL","description":"The findings of the study provide insights into vaccines or treatments to protect people from severe malaria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/","og_locale":"en_US","og_type":"article","og_title":"Stopping severe malaria by harnessing natural human antibodies | EMBL","og_description":"The findings of the study provide insights into vaccines or treatments to protect people from severe malaria.","og_url":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2024-11-20T16:01:04+00:00","article_modified_time":"2024-11-20T16:01:11+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg","type":"image\/jpeg"}],"author":"Carla Manzanas","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Carla Manzanas","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/"},"author":{"name":"Carla Manzanas","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/40c2c3096ae3f56b1304b22fb8c0efb1"},"headline":"Stopping severe malaria by harnessing natural human antibodies","datePublished":"2024-11-20T16:01:04+00:00","dateModified":"2024-11-20T16:01:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/"},"wordCount":2493,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg","keywords":["barcelona","bernabeu","cerebral malaria","malaria","tissue biology"],"articleSection":["Science &amp; Technology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/","url":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/","name":"Stopping severe malaria by harnessing natural human antibodies | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg","datePublished":"2024-11-20T16:01:04+00:00","dateModified":"2024-11-20T16:01:11+00:00","description":"The findings of the study provide insights into vaccines or treatments to protect people from severe malaria.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/science-technology\/stopping-severe-malaria-by-harnessing-natural-human-antibodies\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg","width":1000,"height":600,"caption":"Viola Introini and Maria Bernabeu, authors of a new study on antibodies against virulent proteins responsible for severe malaria, at the PRBB. Credit: Carla Manzanas\/EMBL"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/40c2c3096ae3f56b1304b22fb8c0efb1","name":"Carla Manzanas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/14ed25b349f20c950811a10cef35721ed66d9f8d136445e2d53bb0dd811984f1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/14ed25b349f20c950811a10cef35721ed66d9f8d136445e2d53bb0dd811984f1?s=96&d=mm&r=g","caption":"Carla Manzanas"},"url":"https:\/\/www.embl.org\/news\/author\/carlamanzanas-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2--2\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2024\/11\/20241111_BCN_quickfix-e1732009881993.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/71803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/94"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=71803"}],"version-history":[{"count":12,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/71803\/revisions"}],"predecessor-version":[{"id":71897,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/71803\/revisions\/71897"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/71805"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=71803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=71803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=71803"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=71803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}